Imexpharm Corp - Asset Resilience Ratio

Latest as of March 2026: 13.68%

Imexpharm Corp (IMP) has an Asset Resilience Ratio of 13.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check IMP strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₫386.02 Billion

≈ $14.67 Million USD Cash + Short-term Investments

Total Assets

₫2.82 Trillion

≈ $107.18 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Imexpharm Corp's Asset Resilience Ratio has changed over time. See IMP net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Imexpharm Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Imexpharm Corp (IMP) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₫0.00	0%
Short-term Investments	₫386.02 Billion	13.68%
Total Liquid Assets	₫386.02 Billion	13.68%

Asset Resilience Insights

Moderate Liquidity: Imexpharm Corp has 13.68% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Imexpharm Corp Industry Peers by Asset Resilience Ratio

Compare Imexpharm Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Imexpharm Corp (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Imexpharm Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	7.62%	₫212.10 Billion ≈ $8.06 Million	₫2.78 Trillion ≈ $105.72 Million	+1.95pp
2024-12-31	5.67%	₫142.00 Billion ≈ $5.40 Million	₫2.50 Trillion ≈ $95.17 Million	+1.78pp
2023-12-31	3.89%	₫93.00 Billion ≈ $3.53 Million	₫2.39 Trillion ≈ $90.90 Million	-5.39pp
2022-12-31	9.28%	₫211.30 Billion ≈ $8.03 Million	₫2.28 Trillion ≈ $86.51 Million	+4.38pp
2021-12-31	4.90%	₫112.45 Billion ≈ $4.27 Million	₫2.29 Trillion ≈ $87.18 Million	+1.87pp
2020-12-31	3.03%	₫63.61 Billion ≈ $2.42 Million	₫2.10 Trillion ≈ $79.65 Million	+2.75pp
2019-12-31	0.28%	₫5.19 Billion ≈ $197.09K	₫1.85 Trillion ≈ $70.18 Million	--

pp = percentage points

About Imexpharm Corp

VN:IMP Vietnam Drug Manufacturers - Specialty & Generic

Market Cap

$269.75 Million

₫7.10 Trillion VND

Market Cap Rank

#15454 Global

#85 in Vietnam

Share Price

₫46100.00

Change (1 day)

-0.11%

52-Week Range

₫45300.00 - ₫56700.00

All Time High

₫97000.00